belzutifan – Talk Bio

Actionable Insights Powered by AI

ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns

7 months ago talkbio0Tagged belzutifan, Co., ESMO, LITESPARK-005 trial, Overall Survival, Progression-Free Survival, Renal Cell Carcinoma, Welireg

Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial